<?xml version="1.0" encoding="UTF-8"?>
<gtr:projectOverview xmlns:gtr="http://gtr.ukri.org/api"><gtr:projectComposition><gtr:collaborations><gtr:collaborator url="http://gtr.ukri.org:80/organisation/3EAE04CA-9D62-4483-B9C4-F91AD9F4C5A9"><gtr:id>3EAE04CA-9D62-4483-B9C4-F91AD9F4C5A9</gtr:id><gtr:name>University of Oxford</gtr:name><gtr:address><gtr:line1>University Chest</gtr:line1><gtr:line2>Wellington Square</gtr:line2><gtr:line4>Oxford</gtr:line4><gtr:postCode>OX1 2JD</gtr:postCode><gtr:region>South East</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/46387D84-F71E-4B7D-8C7D-9C288F113510"><gtr:id>46387D84-F71E-4B7D-8C7D-9C288F113510</gtr:id><gtr:name>Imperial College London</gtr:name><gtr:address><gtr:line1>South Kensington Campus</gtr:line1><gtr:line2>Exhibition Road</gtr:line2><gtr:line4>London</gtr:line4><gtr:postCode>SW7 2AZ</gtr:postCode><gtr:region>London</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address></gtr:collaborator></gtr:collaborations><gtr:leadResearchOrganisation url="http://gtr.ukri.org:80/organisation/EDB67137-AF95-475C-954C-8EA1517069D6"><gtr:id>EDB67137-AF95-475C-954C-8EA1517069D6</gtr:id><gtr:name>Nat Inst for Bio Standards and Control</gtr:name><gtr:department>Division of Virology</gtr:department><gtr:address><gtr:line1>Blanche Lane</gtr:line1><gtr:line2>South Mimms</gtr:line2><gtr:line4>Potters Bar</gtr:line4><gtr:line5>Hertfordshire</gtr:line5><gtr:postCode>EN6 3QG</gtr:postCode><gtr:region>East of England</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:typeInd>RO</gtr:typeInd></gtr:leadResearchOrganisation><gtr:organisationRoles><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/EDB67137-AF95-475C-954C-8EA1517069D6"><gtr:id>EDB67137-AF95-475C-954C-8EA1517069D6</gtr:id><gtr:name>Nat Inst for Bio Standards and Control</gtr:name><gtr:address><gtr:line1>Blanche Lane</gtr:line1><gtr:line2>South Mimms</gtr:line2><gtr:line4>Potters Bar</gtr:line4><gtr:line5>Hertfordshire</gtr:line5><gtr:postCode>EN6 3QG</gtr:postCode><gtr:region>East of England</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>LEAD_RO</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/3EAE04CA-9D62-4483-B9C4-F91AD9F4C5A9"><gtr:id>3EAE04CA-9D62-4483-B9C4-F91AD9F4C5A9</gtr:id><gtr:name>University of Oxford</gtr:name><gtr:address><gtr:line1>University Chest</gtr:line1><gtr:line2>Wellington Square</gtr:line2><gtr:line4>Oxford</gtr:line4><gtr:postCode>OX1 2JD</gtr:postCode><gtr:region>South East</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/46387D84-F71E-4B7D-8C7D-9C288F113510"><gtr:id>46387D84-F71E-4B7D-8C7D-9C288F113510</gtr:id><gtr:name>Imperial College London</gtr:name><gtr:address><gtr:line1>South Kensington Campus</gtr:line1><gtr:line2>Exhibition Road</gtr:line2><gtr:line4>London</gtr:line4><gtr:postCode>SW7 2AZ</gtr:postCode><gtr:region>London</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole></gtr:organisationRoles><gtr:personRoles><gtr:personRole url="http://gtr.ukri.org:80/person/6FC4BB73-A97A-4E27-AF06-39D123FB1570"><gtr:id>6FC4BB73-A97A-4E27-AF06-39D123FB1570</gtr:id><gtr:firstName>Neil</gtr:firstName><gtr:otherNames>Mark</gtr:otherNames><gtr:surname>Almond</gtr:surname><gtr:roles><gtr:role><gtr:name>PRINCIPAL_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.ukri.org:80/person/A181FD3D-F540-4D3B-9D83-514FFD53DC26"><gtr:id>A181FD3D-F540-4D3B-9D83-514FFD53DC26</gtr:id><gtr:firstName>Neil</gtr:firstName><gtr:surname>Berry</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.ukri.org:80/person/A4C60447-BBB2-4340-963A-2F88B11682F5"><gtr:id>A4C60447-BBB2-4340-963A-2F88B11682F5</gtr:id><gtr:firstName>Mark</gtr:firstName><gtr:surname>Page</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole></gtr:personRoles><gtr:project url="http://gtr.ukri.org:80/projects?ref=G0601201"><gtr:id>E7E04F8D-F1F5-4C49-8E55-E54A414175A3</gtr:id><gtr:title>THE ROLE OF VACCINE PERSISTENCE IN PROTECTION CONFERRED BY LIVE ATTENUATED SIV</gtr:title><gtr:status>Closed</gtr:status><gtr:grantCategory>Research Grant</gtr:grantCategory><gtr:grantReference>G0601201</gtr:grantReference><gtr:abstractText>The World Health Organisation recognises HIV/AIDS as the number one infectious disease in the world. Doctors and scientists know that the best way to stop this disease would be to develop a vaccine to stop the 14,000 new infections with AIDS virus that occur each day worldwide. 

The difficulty is that scientists do not know whether an AIDS vaccine needs to stimulate the production of antibodies, molecules in the blood that recognise the virus and stop it from infecting new cells or killer T cells that eliminate virus infected cells before the infection spreads further. Alternatively the vaccine may need to do something different to be fully effective. 

The team at NIBSC are studying an animal model of HIV and have found that animals vaccinated with a disabled form of the virus first are resistant to disease causing strains. They are collaborating with scientists in Amsterdam who have a genetically engineered AIDS virus that can only grow if it is given a special drug. The team at NIBSC will use this new virus to understand how the disabled AIDS virus works as a vaccine. That information will put us one step closer to the vaccine that the world desperately needs.</gtr:abstractText><gtr:technicalSummary>A safe and effective vaccine that will prevent infection with and the transmission of HIV is urgently needed to control the AIDS pandemic. However, progress has been hampered by the absence of a clear paradigm of the types of host responses required to prevent or clear infection. Using simian models of AIDS, the most potent vaccine protection has been obtained by vaccination with live, attenuated simian immunodeficiency virus (SIV). However, attempts to characterise the mechanism of protection have, so far, failed. The purpose of this proposal is to investigate the role of the persistence of the attenuated vaccine virus in the vaccine protection observed. To do so, we propose to collaborate with a team led by Prof B Berkhout at the Amsterdam Medical Centre, The Netherlands, to establish, in cynomolgus macaques, a model using a conditional, live, attenuated SIV vaccine that will enable us to modify vaccination schedules and allow us to dissect the process of vaccination. Careful molecular engineering by the Dutch team has yielded a virus that is absolutely dependent upon the presence of the antibiotic doxycycline for replication in vitro. The team at NIBSC will be the first group in the world to use this virus for studies in vivo. We propose to investigate: (1) the kinetics of replication of this virus over 25 weeks in a group of macaques treated with doxycycline. (2) the kinetics of virus replication decay following withdrawal of doxycycline 3 weeks after inoculation of the virus. (3) adaptive immune responses and other host responses (eg. innate immunity, occlusion of viral receptors and depletion of target cells) in groups vaccinated for either 25 weeks or 3 weeks whilst under continuous treatment on doxycycline and compare these responses with those in a group vaccinated for 3 weeks in the presence of doxycyline before withdrawal of the antibiotic for a further 22 weeks. (4) the ability of the 3 vaccine groups described above to prevent and/or control infection following intravenous challenge with a heterologous wild-type SIV stock. The successful outcome of this study will be the establishment of a novel simian model for dissecting host responses to vaccine protection mediated by live attenuated SIV. In addition, we shall have determined the duration of vaccination required to protect against wild-type virus challenge and, critically, whether persistence of the vaccine virus is central to this protection.</gtr:technicalSummary><gtr:fund><gtr:end>2010-10-31</gtr:end><gtr:funder url="http://gtr.ukri.org:80/organisation/C008C651-F5B0-4859-A334-5F574AB6B57C"><gtr:id>C008C651-F5B0-4859-A334-5F574AB6B57C</gtr:id><gtr:name>MRC</gtr:name></gtr:funder><gtr:start>2007-05-01</gtr:start><gtr:type>INCOME_ACTUAL</gtr:type><gtr:valuePounds>708640</gtr:valuePounds></gtr:fund><gtr:output><gtr:artisticAndCreativeProductOutputs/><gtr:collaborationOutputs><gtr:collaborationOutput><gtr:collaboratingOrganisation>University of Oxford</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:department>Department of Experimental Psychology</gtr:department><gtr:description>Neuroinflammation and Neurocognitive Decline in HIV</gtr:description><gtr:id>DEE8EF58-7E9F-4D84-A148-C74CE9581A3C</gtr:id><gtr:impact>Submission to Wellcome Trust for Strategic Award. The award was ultimately declined</gtr:impact><gtr:outcomeId>AP1ZYg9UmAR-2</gtr:outcomeId><gtr:partnerContribution>Imperial College at St Mary's Hospital provide comparative clinical data from HIV infected individuals on Anti-Retroviral Therapies but developing Neurocognitive decline.
Dept of Experimental Psychology, University of Oxford bring expertise in MRI and measuring neurocognitive capacity of NHP's</gtr:partnerContribution><gtr:piContribution>Characterising the neuropathology following infection with attenuated SIV including doxycycline dependent SIV in an NHP model of HIV/AIDS</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2012-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Imperial College London</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:department>Faculty of Medicine</gtr:department><gtr:description>Neuroinflammation and Neurocognitive Decline in HIV</gtr:description><gtr:id>8D9057C1-9678-4244-A55D-47C45823285D</gtr:id><gtr:impact>Submission to Wellcome Trust for Strategic Award. The award was ultimately declined</gtr:impact><gtr:outcomeId>AP1ZYg9UmAR-1</gtr:outcomeId><gtr:partnerContribution>Imperial College at St Mary's Hospital provide comparative clinical data from HIV infected individuals on Anti-Retroviral Therapies but developing Neurocognitive decline.
Dept of Experimental Psychology, University of Oxford bring expertise in MRI and measuring neurocognitive capacity of NHP's</gtr:partnerContribution><gtr:piContribution>Characterising the neuropathology following infection with attenuated SIV including doxycycline dependent SIV in an NHP model of HIV/AIDS</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2012-01-01</gtr:start></gtr:collaborationOutput></gtr:collaborationOutputs><gtr:disseminationOutputs/><gtr:exploitationOutputs/><gtr:furtherFundingOutputs/><gtr:impactSummaryOutputs/><gtr:intellectualPropertyOutputs/><gtr:otherResearchOutputs/><gtr:policyInfluenceOutputs/><gtr:productOutputs/><gtr:researchDatabaseAndModelOutputs/><gtr:researchMaterialOutputs><gtr:researchMaterialOutput><gtr:description>We have established methods for the persistent infection of cynomolgus macaques with a doxycyline dependent attenuated SIV. This involves positive reinforcement training of macaques to accept oral dosing with doxycyline mixed with sweet drink or food</gtr:description><gtr:id>4A5DED9A-829B-4BE9-965A-9BE880670C11</gtr:id><gtr:impact>The development of this technique has enabled us to evaluate the role of attenuated SIV persistence in the maturation of vaccine protection in vivo</gtr:impact><gtr:outcomeId>GkHWKfYhs5j</gtr:outcomeId><gtr:providedToOthers>false</gtr:providedToOthers><gtr:title>Delivery of doxycycline dependent live attenuated simian immunodeficiency virus in cynomolgus macaques</gtr:title><gtr:type>Model of mechanisms or symptoms - mammalian in vivo</gtr:type></gtr:researchMaterialOutput></gtr:researchMaterialOutputs><gtr:softwareAndTechnicalProductOutputs/><gtr:spinOutOutputs/></gtr:output><gtr:publications><gtr:publication><gtr:id>4469F621-858E-4479-BD37-C36C90603A00</gtr:id><gtr:title>International multicenter study to assess a panel of reference materials for quantification of simian immunodeficiency virus RNA in plasma.</gtr:title><gtr:parentPublicationTitle>Journal of clinical microbiology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/ce0e6cc60fcf8c388fd4f1cec0256300"><gtr:id>ce0e6cc60fcf8c388fd4f1cec0256300</gtr:id><gtr:otherNames>Ham C</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>0095-1137</gtr:issn><gtr:outcomeId>CkPN4ee76X6</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>C6AD6A1F-7F48-4F5E-963B-481C513DF083</gtr:id><gtr:title>Heterologous protection elicited by candidate monomeric recombinant HIV-1 gp120 vaccine in the absence of cross neutralising antibodies in a macaque model.</gtr:title><gtr:parentPublicationTitle>Retrovirology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/6c19689ee331bac7aecb68c4f25c1a58"><gtr:id>6c19689ee331bac7aecb68c4f25c1a58</gtr:id><gtr:otherNames>Page M</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>1742-4690</gtr:issn><gtr:outcomeId>pm_14069_29_22799593</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>C51F98FB-03DD-46D7-A14B-2BCF3361E800</gtr:id><gtr:title>Neuropathology of wild-type and nef-attenuated T cell tropic simian immunodeficiency virus (SIVmac32H) and macrophage tropic neurovirulent SIVmac17E-Fr in cynomolgus macaques.</gtr:title><gtr:parentPublicationTitle>Journal of neurovirology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/460297912028122bb9dd14e610a4c745"><gtr:id>460297912028122bb9dd14e610a4c745</gtr:id><gtr:otherNames>Clarke S</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>1355-0284</gtr:issn><gtr:outcomeId>pm_14069_29_22403025</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>E35114B3-221A-4146-843D-FA8BB72C4A33</gtr:id><gtr:title>Mhc haplotype H6 is associated with sustained control of SIVmac251 infection in Mauritian cynomolgus macaques.</gtr:title><gtr:parentPublicationTitle>Immunogenetics</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/12e461ed539902057e92f9c71754dee6"><gtr:id>12e461ed539902057e92f9c71754dee6</gtr:id><gtr:otherNames>Mee ET</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2009-01-01</gtr:date><gtr:issn>0093-7711</gtr:issn><gtr:outcomeId>7591AB3AC9F</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>E506D494-A183-4456-A778-8CD944397FA2</gtr:id><gtr:title>Preparation and characterization of new challenge stocks of SIVmac32H J5 following rapid serial passage of virus in vivo.</gtr:title><gtr:parentPublicationTitle>Journal of medical primatology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/02766ea99fdc02271ba31905900e4123"><gtr:id>02766ea99fdc02271ba31905900e4123</gtr:id><gtr:otherNames>Ferguson D</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2007-01-01</gtr:date><gtr:issn>0047-2565</gtr:issn><gtr:outcomeId>787059B1393</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>EDF95A0C-0792-4830-A4D6-CC050870BBD1</gtr:id><gtr:title>A sensitive cell-based assay to measure the doxycycline concentration in biological samples.</gtr:title><gtr:parentPublicationTitle>Human gene therapy</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/2dabefbe1c40d9b4e1d6130bef59756e"><gtr:id>2dabefbe1c40d9b4e1d6130bef59756e</gtr:id><gtr:otherNames>Kleibeuker W</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2009-01-01</gtr:date><gtr:issn>1043-0342</gtr:issn><gtr:outcomeId>982A6AFFDE1</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>8844F9F8-3FAF-4568-9122-F2BF0DC00964</gtr:id><gtr:title>Upregulation of TRIM5a gene expression after live-attenuated simian immunodeficiency virus vaccination in Mauritian cynomolgus macaques, but TRIM5a genotype has no impact on virus acquisition or vaccination outcome.</gtr:title><gtr:parentPublicationTitle>The Journal of general virology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/2d601c726d34be556fecbbd27cb08186"><gtr:id>2d601c726d34be556fecbbd27cb08186</gtr:id><gtr:otherNames>Mattiuzzo G</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>0022-1317</gtr:issn><gtr:outcomeId>pm_14069_29_23152371</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>166BAB85-7E43-403C-B5C0-F06729B59B45</gtr:id><gtr:title>Complement-mediated virus infectivity neutralisation by HLA antibodies is associated with sterilising immunity to SIV challenge in the macaque model for HIV/AIDS.</gtr:title><gtr:parentPublicationTitle>PloS one</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/6c19689ee331bac7aecb68c4f25c1a58"><gtr:id>6c19689ee331bac7aecb68c4f25c1a58</gtr:id><gtr:otherNames>Page M</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>1932-6203</gtr:issn><gtr:outcomeId>5460894b067da9.02804677</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>590A01FD-24F0-4652-9CFB-9F90DD45CBE2</gtr:id><gtr:title>Specificity of anti-human leukocyte antigen antibody responses after immunization with Remune, an inactivated HIV-1 vaccine.</gtr:title><gtr:parentPublicationTitle>AIDS (London, England)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/6c19689ee331bac7aecb68c4f25c1a58"><gtr:id>6c19689ee331bac7aecb68c4f25c1a58</gtr:id><gtr:otherNames>Page M</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2007-01-01</gtr:date><gtr:issn>0269-9370</gtr:issn><gtr:outcomeId>18586865BA6</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>0CC8D06A-DF29-492F-AD44-17EE7AF671A8</gtr:id><gtr:title>MHC heterozygote advantage in simian immunodeficiency virus-infected Mauritian cynomolgus macaques.</gtr:title><gtr:parentPublicationTitle>Science translational medicine</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/a96081bc737c666c90b62c3f6386d296"><gtr:id>a96081bc737c666c90b62c3f6386d296</gtr:id><gtr:otherNames>O'Connor SL</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>1946-6234</gtr:issn><gtr:outcomeId>C4CA0A05_8C4CA0A05_8</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>AD408131-D4F6-40BF-B544-3230C526FE0D</gtr:id><gtr:title>Early potent protection against heterologous SIVsmE660 challenge following live attenuated SIV vaccination in Mauritian cynomolgus macaques.</gtr:title><gtr:parentPublicationTitle>PloS one</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/3dd8773027f8192fe964ca758e49a370"><gtr:id>3dd8773027f8192fe964ca758e49a370</gtr:id><gtr:otherNames>Berry N</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>1932-6203</gtr:issn><gtr:outcomeId>LXEp3iCT5MB</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>91BD8A77-DC52-4309-BDED-2B729CD405A9</gtr:id><gtr:title>Live attenuated simian immunodeficiency virus vaccination confers superinfection resistance against macrophage-tropic and neurovirulent wild-type SIV challenge.</gtr:title><gtr:parentPublicationTitle>The Journal of general virology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/3dd8773027f8192fe964ca758e49a370"><gtr:id>3dd8773027f8192fe964ca758e49a370</gtr:id><gtr:otherNames>Berry N</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>0022-1317</gtr:issn><gtr:outcomeId>56e053d2b014b2.55738342</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>4247E7CD-4A54-4330-B0A0-8C07DCF6BCBA</gtr:id><gtr:title>Resistance to superinfection by a vigorously replicating, uncloned stock of simian immunodeficiency virus (SIVmac251) stimulates replication of a live attenuated virus vaccine (SIVmacC8).</gtr:title><gtr:parentPublicationTitle>The Journal of general virology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/3dd8773027f8192fe964ca758e49a370"><gtr:id>3dd8773027f8192fe964ca758e49a370</gtr:id><gtr:otherNames>Berry N</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2008-01-01</gtr:date><gtr:issn>0022-1317</gtr:issn><gtr:outcomeId>5AAD47B04B2</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>5701F2DE-2C90-40B7-B635-E9DD2882C387</gtr:id><gtr:title>Role of Occult and Post-acute Phase Replication in Protective Immunity Induced with a Novel Live Attenuated SIV Vaccine.</gtr:title><gtr:parentPublicationTitle>PLoS pathogens</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/3dd8773027f8192fe964ca758e49a370"><gtr:id>3dd8773027f8192fe964ca758e49a370</gtr:id><gtr:otherNames>Berry N</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>1553-7366</gtr:issn><gtr:outcomeId>58a33fe6837e78.72812834</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>4DA2ACD4-A1FF-4AAB-A440-8384AA3140D7</gtr:id><gtr:title>Immune Responses in the Central Nervous System Are Anatomically Segregated in a Non-Human Primate Model of Human Immunodeficiency Virus Infection.</gtr:title><gtr:parentPublicationTitle>Frontiers in immunology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/3c0283dd96b349de1ebf08f918148ca4"><gtr:id>3c0283dd96b349de1ebf08f918148ca4</gtr:id><gtr:otherNames>Tavano B</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>1664-3224</gtr:issn><gtr:outcomeId>5aa8e13ec8a9d3.93603546</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>EDC8CFA6-C6C2-48E7-8684-9B4B371FFEF9</gtr:id><gtr:title>MHC haplotype frequencies in a UK breeding colony of Mauritian cynomolgus macaques mirror those found in a distinct population from the same geographic origin.</gtr:title><gtr:parentPublicationTitle>Journal of medical primatology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/12e461ed539902057e92f9c71754dee6"><gtr:id>12e461ed539902057e92f9c71754dee6</gtr:id><gtr:otherNames>Mee ET</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2009-01-01</gtr:date><gtr:issn>0047-2565</gtr:issn><gtr:outcomeId>B9FFE83AACD</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>ED3517F0-47A3-47D8-BF72-295A8BCFF5D2</gtr:id><gtr:title>Attenuated SIV causes persisting neuroinflammation in the absence of a chronic viral load and neurotoxic antiretroviral therapy.</gtr:title><gtr:parentPublicationTitle>AIDS (London, England)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/02766ea99fdc02271ba31905900e4123"><gtr:id>02766ea99fdc02271ba31905900e4123</gtr:id><gtr:otherNames>Ferguson D</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>0269-9370</gtr:issn><gtr:outcomeId>58a33f473fb9a0.15260078</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>93766DD3-9EBE-459B-A790-8C7202F080E3</gtr:id><gtr:title>Optimization of the doxycycline-dependent simian immunodeficiency virus through in vitro evolution.</gtr:title><gtr:parentPublicationTitle>Retrovirology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/4ac15855ba6b861ceec45af3d9639908"><gtr:id>4ac15855ba6b861ceec45af3d9639908</gtr:id><gtr:otherNames>Das AT</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2008-01-01</gtr:date><gtr:issn>1742-4690</gtr:issn><gtr:outcomeId>ED6575BC58F</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>D0CB2FE4-0F8C-4E25-89F3-BD2B21188000</gtr:id><gtr:title>Immunogenicity of a recombinant measles HIV-1 subtype C vaccine.</gtr:title><gtr:parentPublicationTitle>Vaccine</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/242045ab417d294ec99a5f569db09bfe"><gtr:id>242045ab417d294ec99a5f569db09bfe</gtr:id><gtr:otherNames>Stebbings R</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>0264-410X</gtr:issn><gtr:outcomeId>pm_14069_29_24161574</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>EB406832-BDA9-47B6-BF44-752BFB3351A4</gtr:id><gtr:title>Complete Genome Sequence of a Reference Stock of Simian Immunodeficiency Virus RNA (SIVmac251/32H/L28) Determined by Deep Sequencing.</gtr:title><gtr:parentPublicationTitle>Genome announcements</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/be99268a8d5ba7506f852d69202e4f01"><gtr:id>be99268a8d5ba7506f852d69202e4f01</gtr:id><gtr:otherNames>Jenkins A</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:outcomeId>58a33f4778a619.21001018</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>E2026652-1E94-490F-A9C6-B8EF7B7B74A2</gtr:id><gtr:title>Early biodistribution and persistence of a protective live attenuated SIV vaccine elicits localised innate responses in multiple lymphoid tissues.</gtr:title><gtr:parentPublicationTitle>PloS one</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/02766ea99fdc02271ba31905900e4123"><gtr:id>02766ea99fdc02271ba31905900e4123</gtr:id><gtr:otherNames>Ferguson D</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>1932-6203</gtr:issn><gtr:outcomeId>5460831b3df556.07964526</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>F1AC8EDC-6066-41F6-8ED9-283EDDF5DBA9</gtr:id><gtr:title>Conditionally-live attenuated SIV upregulates global T effector memory cell frequency under replication permissive conditions.</gtr:title><gtr:parentPublicationTitle>Retrovirology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/56240d31a307ed3d91893a2f15e9f12a"><gtr:id>56240d31a307ed3d91893a2f15e9f12a</gtr:id><gtr:otherNames>Manoussaka MS</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>1742-4690</gtr:issn><gtr:outcomeId>pm_14069_29_23738926</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>9C62DAC8-AD58-4035-AEE0-5F203955AF80</gtr:id><gtr:title>Mhc haplotype M3 is associated with early control of SHIVsbg infection in Mauritian cynomolgus macaques.</gtr:title><gtr:parentPublicationTitle>Tissue antigens</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/12e461ed539902057e92f9c71754dee6"><gtr:id>12e461ed539902057e92f9c71754dee6</gtr:id><gtr:otherNames>Mee ET</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>0001-2815</gtr:issn><gtr:outcomeId>ePkDvbVx74V</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>1065B746-EDE2-4F3F-A033-F17762A26D1B</gtr:id><gtr:title>Linkage disequilibrium mapping of the replicated type 2 diabetes linkage signal on chromosome 1q.</gtr:title><gtr:parentPublicationTitle>Diabetes</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/8619aabd857174cb3a1267c70922af4b"><gtr:id>8619aabd857174cb3a1267c70922af4b</gtr:id><gtr:otherNames>Prokopenko I</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2009-01-01</gtr:date><gtr:issn>0012-1797</gtr:issn><gtr:outcomeId>pm_540e14ee14e4be147</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>E0E90C7B-0617-4461-930B-B8E7BBC70843</gtr:id><gtr:title>Characterisation of MHC haplotypes in a breeding colony of Indonesian cynomolgus macaques reveals a high level of diversity.</gtr:title><gtr:parentPublicationTitle>Immunogenetics</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/8106cc52ff6d6c564631dd1f147da90d"><gtr:id>8106cc52ff6d6c564631dd1f147da90d</gtr:id><gtr:otherNames>Mitchell JL</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>0093-7711</gtr:issn><gtr:outcomeId>MmjR8CfJx6A</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>7DC7328F-E538-425A-816A-997169FF20E0</gtr:id><gtr:title>Allogeneic lymphocyte transfer in MHC-identical siblings and MHC-identical unrelated Mauritian cynomolgus macaques.</gtr:title><gtr:parentPublicationTitle>PloS one</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/12e461ed539902057e92f9c71754dee6"><gtr:id>12e461ed539902057e92f9c71754dee6</gtr:id><gtr:otherNames>Mee ET</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>1932-6203</gtr:issn><gtr:outcomeId>5460831b6808e8.40983599</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>A2D2DC7D-40DA-4A61-9256-6F98C2E0BE44</gtr:id><gtr:title>The production, characterisation and application of monoclonal antibodies generated by immunisation with HIV-1C clade RGP140 envelope protein.</gtr:title><gtr:parentPublicationTitle>Journal of virological methods</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/4fbd0dcb40fb4688b1476dd0fa22e4cf"><gtr:id>4fbd0dcb40fb4688b1476dd0fa22e4cf</gtr:id><gtr:otherNames>Hassall M</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>0166-0934</gtr:issn><gtr:outcomeId>pm_14069_29_23973741</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>A46BCD5B-77F8-44D5-B2A1-B327C6E81CCB</gtr:id><gtr:title>Immunological responses and viral modulatory effects of vaccination with recombinant modified vaccinia virus Ankara (rMVA) expressing structural and regulatory transgenes of simian immunodeficiency virus (SIVmac32H/J5M).</gtr:title><gtr:parentPublicationTitle>Journal of medical primatology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/3dd8773027f8192fe964ca758e49a370"><gtr:id>3dd8773027f8192fe964ca758e49a370</gtr:id><gtr:otherNames>Berry N</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2007-01-01</gtr:date><gtr:issn>0047-2565</gtr:issn><gtr:outcomeId>7A0D404625C</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>9E387BF5-F3EA-4F20-91BF-EFBAACFEC6DE</gtr:id><gtr:title>Low rates of transmission of SRV-2 and STLV-I to juveniles in a population of Macaca fascicularis facilitate establishment of specific retrovirus-free colonies.</gtr:title><gtr:parentPublicationTitle>Journal of medical primatology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/12e461ed539902057e92f9c71754dee6"><gtr:id>12e461ed539902057e92f9c71754dee6</gtr:id><gtr:otherNames>Mee ET</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2009-01-01</gtr:date><gtr:issn>0047-2565</gtr:issn><gtr:outcomeId>C45CWYJqNE7</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>1835D85A-8F7D-462F-9F3B-9138242375EA</gtr:id><gtr:title>Mucosal immunization in macaques upregulates the innate APOBEC 3G anti-viral factor in CD4(+) memory T cells.</gtr:title><gtr:parentPublicationTitle>Vaccine</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/52542eaf317f347220ec706e5b20b4a1"><gtr:id>52542eaf317f347220ec706e5b20b4a1</gtr:id><gtr:otherNames>Wang Y</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2009-01-01</gtr:date><gtr:issn>0264-410X</gtr:issn><gtr:outcomeId>903D09373D2</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>64B08370-F688-4D9F-AEA8-694EEC700EFA</gtr:id><gtr:title>Horizontal acquisition and a broad biodistribution typify simian foamy virus infection in a cohort of Macaca fascicularis.</gtr:title><gtr:parentPublicationTitle>Virology journal</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/a871e4edd86720363b85cd5525f8bbe7"><gtr:id>a871e4edd86720363b85cd5525f8bbe7</gtr:id><gtr:otherNames>Hood S</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>1743-422X</gtr:issn><gtr:outcomeId>5460831b8ff377.72691846</gtr:outcomeId></gtr:publication></gtr:publications><gtr:identifiers><gtr:identifier type="RCUK">G0601201</gtr:identifier></gtr:identifiers><gtr:healthCategories><gtr:healthCategory><gtr:id>03BA7BC9-C251-48FC-8EA9-5F7414A63FEE</gtr:id><gtr:percentage>100</gtr:percentage><gtr:text>Infection</gtr:text></gtr:healthCategory></gtr:healthCategories><gtr:researchActivities><gtr:researchActivity><gtr:id>D8F3A27D-084A-40BB-A046-087DACE23410</gtr:id><gtr:percentage>100</gtr:percentage><gtr:text>3.4  Vaccines</gtr:text></gtr:researchActivity></gtr:researchActivities><gtr:researchSubjects/><gtr:researchTopics/><gtr:rcukProgrammes/></gtr:project></gtr:projectComposition></gtr:projectOverview>